According to the National Bioscience Report, the US bioscience industry is on course for continued growth.
A recent study analyzing the US bioscience industry growth over the past 11 years, through the recent recession and early economic recovery, reveals positive trends. The industry demonstrated a strong record of growth from 2001-2012.
The report, Battelle/BIO State Bioscience Jobs, Investments and Innovation 2014, the sixth in a biennial series from Battelle and BIO tracking the US bioscience industry, reveals a strong bioscience sector on course for continued growth. The state-by-state industry assessment finds US bioscience firms directly employ 1.62 million people, a figure that includes nearly 111,000 new, high-paying jobs created since 2001.
Within the private sector, the bioscience industry has contributed an additional 6.24 million jobs through the indirect employment effect, yielding a total employment impact of 7.86 million jobs. Furthermore, the bioscience industry continues to create and sustain high-wage jobs, paying an average 80% more than the overall private sector average salary and growing at a faster rate.
The US bioscience industry handled the recession much better than the overall economy and other knowledge-based industries. While national private sector employment fell by 3.1% from the outset of the recession in 2007 through 2012, bioscienceindustry employment fell only 0.4%. Although employment has almost returned to its pre-recession level, the economic output of the bioscience industry has expanded significantly, with 17% growth since 2007, almost twice the national private sector nominal output growth.
Source: http://www.bio.org/articles/battellebio-state-bioscience-jobs-investments-and-innovation-2014
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.